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Aims Scavenger receptor Class B Type 1 (SR-BI) is a major receptor for high-density lipoprotein (HDL) that promotes
hepatic uptake of cholesterol from HDL. A rare mutation p.P376L, in the gene encoding SR-BI, SCARB1, was re-
cently reported to associate with elevated HDL cholesterol (HDL-C) and increased risk of coronary artery disease
(CAD), suggesting that increased HDL-C caused by SR-BI impairment might be an independent marker of cardio-
vascular risk. We tested the hypothesis that alleles in or close to SCARB1 that associate with elevated levels of
HDL-C also associate with increased risk of CAD in the relatively homogeneous population of Iceland.
...................................................................................................................................................................................................
Methods
and results
Using a large resource of whole-genome sequenced Icelanders, we identified thirteen SCARB1 coding mutations
that we examined for association with HDL-C (n= 136 672). Three rare SCARB1 mutations, encoding p.G319V,
p.V111M, and p.V32M (combined allelic frequency = 0.2%) associate with elevated levels of HDL-C (p.G319V:
b= 11.1 mg/dL, P= 8.0 10-7; p.V111M: b= 8.3 mg/dL, P= 1.1 10-6; p.V32M: b= 10.2 mg/dL, P= 8.1 10-4). These
mutations do not associate with CAD (36 886 cases/306 268 controls) (odds ratio = 0.90, 95% confidence interval
0.67–1.22, P= 0.49), despite effects on HDL-C comparable to that reported for p.P376L, both in terms of direction
and magnitude. Furthermore, HDL-C raising alleles of three common SCARB1 non-coding variants, including one
previously unreported (rs61941676-C: b= 1.25 mg/dL, P= 1.7 10-18), and of one low frequency coding variant
(p.V135I) that independently associate with higher HDL-C, do not confer increased risk of CAD.
...................................................................................................................................................................................................
Conclusion Elevated HDL-C due to genetically compromised SR-BI function is not a marker of CAD risk.
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Introduction
Despite marked improvements in treatment and prevention, cardio-
vascular diseases remain the most common cause of death in Iceland
like in other European countries.1 Epidemiological studies consist-
ently show an inverse relationship between levels of high-density
lipoprotein cholesterol (HDL-C) and the risk of coronary artery dis-
ease (CAD).2 This relationship has been explained by a potential anti-
atherogenic properties of HDL, including its role in reverse
cholesterol transport,3 in which cholesterol from peripheral tissues is
returned to the liver for excretion in bile. However, neither
Mendelian randomization studies4–6 nor interventional studies7–9
support the notion that HDL-C directly protects against CAD. This
implies that HDL-C is not antiatherogenic itself, but rather a marker
of other antiatherogenic factors. Accordingly, the most recent
European Society of Cardiology and European Atherosclerosis
Society Guidelines for the management of dyslipidaemias10 do not
recommend HDL-C as a target for treatment.
A recent study reported that a rare missense mutation p.P376L in
SCARB1 encoding the scavenger receptor Class B Type I (SR-BI), as-
sociates with impaired function of the encoded protein and elevated
HDL-C levels.11 The mutation was also found to associate with CAD
in a meta-analysis of 16 studies with an odds ratio (OR) of 1.79 and
P= 0.018. The investigators concluded that reduced hepatic SR-BI
function in humans causes impaired reverse cholesterol transport,
leading to increased risk of CAD.11 This would suggest that high
HDL-C might in some cases be an independent marker of increased
risk of cardiovascular disease.12 However, given the extremely low
and variable carrier rate of the mutation between study groups
(overall 86 carriers in 137 995 or 1 in 1600 individuals), the possibility
has been raised,13 that the p.P376L variant may be an indirect marker
for a substratum of the population.
Scavenger receptor Class B Type 1, an integral membrane protein
expressed most abundantly in the liver and endocrine organs that
make steroids, is a receptor for HDL. Mouse studies have demon-
strated that SR-BI plays a key role in reverse cholesterol transport,
promoting the hepatic selective uptake of cholesterol from HDL14
and facilitating the secretion of cholesterol into bile.15 In SR-BI defi-
cient mice biliary cholesterol is decreased, but HDL-C levels in blood
are elevated,16,17 and there is acceleration of atherosclerosis.18,19
Hepatic overexpression of SR-BI in mice has the opposite effect;
enhanced hepatocellular cholesterol uptake and increased choles-
terol secretion to bile,15,16,20 lower levels of circulating HDL-C,15
and attenuated atherosclerosis.21,22 Scavenger receptor Class B
Type 1 up-regulation in mouse models is also associated with biliary
cholesterol hypersecretion and increased gallstone formation.23
The effects of SR-BI mutations on HDL-C levels in humans have
been clearly demonstrated.11,24,25 Three rare missense mutations in
SCARB1,24,25 other than the mutation encoding p.P376L, were re-
ported to have HDL-C increasing effects comparable to that of
p.P376L (8.4–18.9 mg/dL). In addition, genome wide association studies
(GWAS) have found two common non-coding variants within the
SCARB1 locus that associate with HDL-C levels,6,26 both with small ef-
fects relative to those of the rare coding ones. Neither the rare variants
(encoding p.297S, p.S112F, and p.T175A),24,25 nor the common HDL-
C associating variants6 have been reported to associate with CAD,
although, we note that the sample sizes in the studies describing the
rare mutations may have been too small to detect such an association.
In view of the contradictory results of previous studies, assessing
the effects of rare SCARB1 variants on the risk of CAD, a further in-
quiry is called for. Herein, we use the relatively homogeneous popu-
lation of Iceland to test the hypothesis that alleles in or close to
SCARB1 that associate with elevated levels of HDL-C also associate
with increased risk of CAD. Further, we examine whether SCARB1
variants that associate with HDL-C in humans alter the susceptibility
to gallstone formation,27 as suggested by mouse models.15,23
Methods
The study was approved by The National Bioethics Committee in Iceland
(Approval no. 07–085, with amendments) and the Data Protection
Authority of Iceland (Approval no.2007060474ThS/—, with amendments).
All participating subjects donating samples signed informed consents.
Personal identities of the phenotypes and biological samples were encrypted
by a third party system provided by the Icelandic Data Protection Authority.
Enrolment of participants, the phenotypic definitions for CAD, infor-
mation on lipid measurements, genotyping, imputation methods, and as-
sociation analysis have previously been described in detail5,28–31 (see also
Supplementary material online, Note). Briefly, lipid measurements were
obtained from three of the largest clinical laboratories in Iceland. We
used HDL-C measurements from 136 672 Icelanders, 93 169 were chip-
typed and directly imputed, and 43 503 were first and second degree rela-
tives of chip-typed individuals and had their genotypes inferred based on
genealogy. Coronary artery disease cases (n= 36 886 of which 17 591
were chip-typed) were identified based on International Classification of
Diseases-9 and 10 discharge codes from Landspitali—The National
University Hospital of Iceland, and from death registries. The controls
(n= 306 268 of which 121 163 were chip-typed) included population con-
trols from the Icelandic genealogical database and individuals recruited
through different genetic studies at deCODE genetics. Description of
genetic risk scores is provided in Supplementary material online, Note.
Results and discussion
Using our population-based resource of 8453 whole-genome
sequenced Icelanders, we identified thirteen SCARB1 coding variants
Translational perspective
The current study shows that decreased function of Scavenger receptor Class B Type 1 (SR-BI), resulting in reduced hepatic reverse choles-
terol transport and increased high-density lipoprotein cholesterol levels, does not translate into increased coronary artery disease risk. Thus,
increasing hepatic reverse cholesterol transport through pharmacological activation of SR-B1 is not likely to improve outcome. However, the
study provides evidence that modulating other functions of SR-BI might do so. The results highlight the complexities of potential therapeutic
development with SR-BI modulating agents.
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..and one splice region variant (Supplementary material online,
Table S1) that we imputed into chip-genotyped Icelanders and their
close relatives28–31 and tested for association with HDL-C
(n= 136 672). Three very rare SCARB1 missense variants that never
occur together on the same chromosome, p.G319V, p.V111M, and
p.V32M (allelic frequency 0.056%, 0.111%, and 0.026%, respectively)
associate with elevated levels of HDL-C (p.G319V: b= 11.1 mg/dL,
P= 8.0 10-7; p.V111M: b= 8.3 mg/dL, P= 1.1 10-6; p.V32M:
b= 10.2 mg/dL, P= 8.1 10-4) (Table 1). The associations of these
variants with HDL-C have not been reported before. Overall, one in
250 Icelanders carries one of these three variants and none of them
associates with other lipid fractions (Supplementary material online,
Table S3). Although the missense variants p.P376L, p.P297S, p.S112F,
and p.T175A previously reported to associate with increased HDL-
C11,24,25 (reported effects: 8.4–18.9 mg/dL) were not observed in
Iceland, the three rare missense variants identified have effects in the
same direction and of comparable magnitude (8–11 mg/dL) as the
published ones. Similar to all previously described HDL-C increasing
variants in SCARB1,11,24,25 the variants encoding p.G319V and
p.V111M occur in the large extracellular loop of the SR-BI protein,
within highly conserved regions and are predicted to be damaging
(Supplementary material online, Table S1). The missense variant
p.V32M is predicted to be benign, and is in a region less conserved
between species (Supplementary material online, Table S1). In add-
ition to the rare variants, we observed one low frequency missense
variant p.V135I (frequency 1.23%) that associates with increased
HDL-C, albeit with considerably less effect (b= 2.1 mg/dL,
P= 6.4 10-6) than the rare ones (Table 1). Two of the rare coding
sequence variants (p.G319V and p.V111M) are reported in the
Genome Aggregation Database (gnomAD at http://gnomad.broadin-
stitute.org, assessed March 2018)32 in European populations, but at
much lower frequencies than in Iceland.
We tested the missense variants encoding p.G319V, p.V111M,
p.V32M, and p.V135I for association with CAD among 36 886 cases
and 306 268 controls (Table 1). None of the variants associates with
CAD risk (P> 0.05). To increase power to detect association we
aggregated the three rare large impact variants p.G319V, p.V111M,
and p.V32M (combined allelic frequency = 0.2%) and tested for asso-
ciation with increased risk of CAD. This aggregate test gives an
ORCAD = 0.90, 95% confidence interval (CI) 0.67–1.22; P= 0.49
(Supplementary material online, Table S2).
We further tested three common non-coding variants that inde-
pendently associate with HDL-C, for association with CAD in
Iceland and in the publicly available CARDIOGRAM/C4D 1000G
data (Table 2). Of these common HDL-C associating variants one is
novel (rs61941676) and two represent previously reported6 GWAS
signals (rs838876 and rs838909) (Supplementary material online,
Note and Table S3). In the combined results from the Icelandic and
CARDIOGRAM/C4D datasets, two of the three common variants
show weak evidence for association with CAD (rs61941676-C:
OR = 0.97, 95% CI 0.95–1.00; P= 0.03 and rs838876-A: OR = 0.98,
95% CI 0.96–0.99; P= 0.0026) (Table 2), with the HDL-C increasing
allele trending towards reduced risk of CAD.
In light of the seemingly discrepant effects of rare SCARB1 variants
on the risk of CAD, it could be argued that the three Icelandic rare
variants that associate with raised HDL-C could do so without
inhibiting the hepatocellular trafficking of cholesterol to bile; thus
explaining the lack of association with CAD. In this scenario, en-
hancement of cholesteryl ester transfer protein (CETP)-mediated
exchange of cholesteryl esters from HDL to apoB containing lipopro-
teins, would counteract the genetically compromized SR-BI, resulting
in minimal or no net effect on the hepatic cholesterol removal in car-
riers of the Icelandic variants. These effects would contrast the hin-
dered hepatic cholesterol uptake observed in the SR-BI deficient
mice (mice do not express CETP) and in hepatocytes derived from
human induced pluripotent stem cells, carrying the p.P376L muta-
tion.11 To test the impact of the Icelandic SCARB1 mutations, and
other HDL-C associating variants at the locus, on transhepatic chol-
esterol flux, we used gallstone risk as a proxy. It has been shown that
gallstone formation largely results from cholesterol hypersecretion
to bile,23,27,33 and in mice, overexpression of SR-BI associates with
biliary cholesterol hypersecretion and increased gallstone formation.
The effects of the SCARB1 variants on gallstone risk was assessed
in 8281 cases and 377 474 controls. Three of the seven HDL-C
........................................... ..............................................
....................................................................................................................................................................................................................
Table 1 Association of SCARB1 locus variants with high-density lipoprotein cholesterol and the corresponding effect
on coronary artery disease
Comment on
variant
Variant type rs-name A1/A2 EA freq.
(%)
HDL-C (n5136 672) CAD (n5 36 886/306 268)
P-value b (mg/dL) SE P-value OR 95% CI
Rare coding Missense (p.319V) rs150728540 A/C 0.056 8.0 10-7 11.119 2.253 0.365 0.788 0.47–1.32
Rare coding Missense (p.V111M) rs5890 T/C 0.111 1.1 10-6 8.254 1.691 0.775 1.063 0.70–1.62
Rare coding Missense (p.V32M) rs771247110 T/C 0.026 8.1 10-4 10.198 3.046 0.377 0.703 0.32–1.54
Low frequency coding Missense (p.V135I) rs5891 T/C 1.226 6.4 10-6 2.063 0.457 0.584 1.031 0.92–1.15
Common novel Intronic rs61941676 A/C 84.8 1.7 10-18 1.245 0.140 1.2 10-3 0.945 0.92–0.98
Common GWAS Downstream rs838876 A/G 34.1 2.4 10-17 0.921 0.107 0.083 0.977 0.95–1.00
Common GWAS Intronic rs838909 G/A 53.9 1.9 10-17 0.870 0.102 0.788 1.003 0.98–1.02
The combined allele frequency for p.G319V, p.V111M, and p.V32M is 0.2% (0.4% carrier frequency). This corresponds to 147 carriers (of any of the three rare HDL-C rais-
ing mutations) among the 36 886 CAD cases and 1225 carriers among the 306 268 controls. Effects, b in mg/dL and OR, are given for the A1, except for rs61941676 and
rs838909 the effects are given for the A2. Variant type, with coding changes in protein sequence NP_001076428.1 given in bracket.
A1, minor allele; A2, major allele; CAD, coronary artery disease; CI, confidence interval; EA freq., effect allelic frequency; GWAS, signal previously reported in genome wide
association study; HDL-C, high-density lipoprotein cholesterol; OR, odds ratio; SE, standard error.
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variants showed nominally significant association with gallstones
(Supplementary material online, Table S3). A genetic risk score for
HDL-C, constructed on the basis of seven SCARB1 HDL-C associat-
ing variants, associates with gallstones. For each standard deviation
(SD), increase in HDL-C due to the genetic risk score, the risk of gall-
stones decreases by 61% (OR = 0.39, 95% CI 0.24–0.63;
P= 1.0 10-4) (Supplementary material online, Table S2). This finding
supports the conclusion that SCARB1 variants associating with
increased HDL-C in humans impair cholesterol excretion through
bile, thus playing a role in the late stages of reverse cholesterol trans-
port, as described in the mouse and for other SCARB1 mutations.11,24
However, in concordance with the results for individual variants, the
SCARB1 HDL-C genetic risk score does not associate with CAD risk
(for one SD of genetically elevated HDL-C: OR = 0.84, 95% CI 0.58–
1.22; P= 0.36, Supplementary material online, Table S2) further tilting
the scale against the hypothesis that hindered flux of HDL-C to the
liver due to SR-BI impairment increases CAD susceptibility in
humans.
Although we have demonstrated that SCARB1 variants leading to
decreased flux of HDL-C to the liver do not increase CAD risk (Take
home figure), other SR-BI functions may still do so. In the Icelandic
data a common SCARB1 intronic variant rs11057837-T (allele
frequency = 9.5%) associates with CAD (OR = 1.11, P= 1.2 10-6)
(Table 2), but not with HDL-C or gallstones after adjusting for HDL-
C variants in the region (Supplementary material online, Table S3 and
Note). Rs11057837-T also associates with CAD in the public 1000G
data from CARDIOGRAM/C4D34 (OR = 1.08 and P= 1.9 10-8 for
Iceland and CARDIOGRAM/C4D combined) (Table 2). The
...................................... ...................................... ...................................... .......................................
...................................... ...................................... ...................................... .......................................
...................................... ...................................... ...................................... .......................................
....................................................................................................................................................................................................................
Table 2 Meta-analyses of the association of SCARB1 locus variants with coronary artery disease in Iceland and
CARDIOGRAM/C4D
CAD variant HDL-C variant HDL-C variant HDL-C variant
rs11057837 [T] rs61941676 [C] rs838876 [A] rs838909 [A]
EA freq.5 9.5% EA freq.584.8% EA freq.5 34.4% EA freq.553.9%
P-value OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value OR (95% CI)
CAD (Iceland) 1.2 10-6 1.108 (1.06–1.15) 0.0012 0.945 (0.92–0.98) 0.137 0.981 (0.96–1.01) 0.788 1.003 (0.98–1.02)
CAD (CARDIOGRAM/C4D) 9.5 10-4 1.058 (1.02–1.09) 0.894 0.998 (0.97–1.03) 7.8 10-3 0.973 (0.95–0.99) 0.177 0.987 (0.97–1.01)
Combined 1.9 10-8 1.08 (1.05–1.11) 0.03 0.97 (0.95–1.00) 2.6 10-3 0.98 (0.96–0.99) 0.40 0.99 (0.98–1.01)
The reported34 CAD variant rs11057830 (R2 = 0.71 with rs11057837) associates with CAD with OR = 1.085, P= 1.6 10-5 in Iceland. Effects are calculated based on the EA
given in [ ]. Results from the Icelandic and CARDIOGRAM/C4D case-control groups were combined using inverse variance weighted fixed effect model.
CAD, coronary artery disease; CI, confidence interval; EA freq., effect allele frequency; EA, effect allele; HDL-C, high-density lipoprotein cholesterol; OR, odds ratio.
No relaonship between elevated HDL-C levels due to genecally compromised SR-BI funcon and increased risk of CAD
Reverse cholesterol transport
HDL-C (n=136,672) CAD (n=36,886/306,268)
SCARB1
coding change
Allele 
frequency 
(%)
P β (mg/dl) SE P OR 95% CI
p.319V 0.056 8.0 × 10-7 11.12 2.25 0.37 0.79 0.47 - 1.32
p.V111M 0.111 1.1 × 10-6 8.25 1.69 0.78 1.06 0.70 - 1.62
p.V32M 0.026 8.1 × 10-4 10.20 3.05 0.38 0.70 0.32 - 1.54
• Scavenger receptor class B, type I (SR-BI), encoded
by the SCARB1 gene is a major receptor for HDL
• Impaired SR-BI funcon hinders ﬂux of cholesterol
from HDL to the liver, resulng in elevated HDL-C
levels
• Three novel SCARB1 missense mutaons encoding
p.G319V, p.V111M, and p.V32M associate with
elevated HDL-C levels
• These HDL-C raising mutaons do not aﬀect CAD
suscepbility in humans
Lipid rich
Lipid poor
Take home ﬁgure Schematic showing the role of SR-BI in reverse cholesterol transport; promoting hepatic uptake of cholesterol from HDL
and cholesterol secretion to bile. Rare missense mutations that compromise this SR-BI function do not affect the risk of coronary artery disease.
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rs11057837 correlates (R2 = 0.7) with other intronic variants
(rs11057841, rs11057830, and rs10846744) that have previously
been found to associate with Lp-PLA2 activity and mass,35 vitamin E
levels,36 subclinical atherosclerosis,37 and with CAD.34,35 The associ-
ation of correlated variants with vitamin E levels support the notion
that rs11057837 mediates its effect through SCARB1, rather than
other genes in the region, since in vitro studies have demonstrated the
influence of SR-BI on tissue antioxidant uptake (vitamin E and carot-
enoids).38,39 These effects, or other functions that have been linked
to SR-BI, such as the effect on endothelial cell nitric oxide metabol-
ism,40 bacterial or viral recognition and degradation,41–43 or induction
of apoptosis,44 are mechanisms that could explain the association of
rs11057837 with CAD. Further, effects on other genes in the region
cannot be ruled out.
To summarize, the HDL-C increasing effects (8–11 mg/dL) of the
three rare SCARB1 missense variants described in our study, encoding
p.G319V, p.V111M, and p.V32M, are comparable to the HDL-C
increasing effects (8–19 mg/dL) of the previously reported variants
(encoding p.P376L, p.P297S, p.S112F, and p.T175A),11,24,25 compat-
ible with similar impact on SR-BI function. The variants do not associ-
ate with risk of CAD, and our estimate of the CAD effect, conferred
by carrying one copy of any of the three rare HDL-C raising muta-
tions (ORCAD = 0.90, 95% CI 0.67–1.22), is significantly different
from the OR of 1.79 reported for p.P376L.11 Importantly the 95% CI
indicates that OR above 1.22 is unlikely. Assuming a true association
between the HDL-C raising variants and increased risk of CAD, we
have 90% power to detect variant association with OR = 1.29 at P-
value <0.05. It is conceivable that the mutation encoding p.P376L has
CAD susceptibility effects that are not shared by other HDL-C rais-
ing variants. However, given that it is relatively specific to Ashkenazi
Jews (carried by about 1 in 20 Ashkenazi Jews vs. about 1 in 10 000
Europeans that are not Ashkenazi Jews)45,46 it is more likely that dif-
ferences in population substructure between cases and controls is
the main explanation of the reported association of p. P376L with
CAD. Specifically, this striking difference in carrier frequency, to-
gether with a relatively small imbalance in the number of Ashkenazi
Jews between CAD cases and controls, could introduce a false asso-
ciation of similar degree as the one reported.11
In conclusion, our results do not support a relationship between
elevated HDL-C levels due to genetically compromised SR-BI func-
tion and increased risk of CAD. These findings are in keeping with re-
cent genetic and interventional studies4–9 failing to show causal
relationship between HDL-C levels and atherosclerosis and support
current dyslipidaemia guidelines.
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